Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996412 | 0.89 | APEX1 (0.70) | APEX1ALDH1A1MAPTCA2MEN1 | |
| SCHEMBL9503748 | 0.84 | MAPT (0.56) | APEX1ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL1995617 | 0.84 | HPGD (0.59) | APEX1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL6515444 | 0.82 | APEX1 (0.51) | APEX1ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL1995492 | 0.80 | MAPT (0.55) | APEX1ALDH1A1MAPTHPGDHSP90AA1 | |
| SCHEMBL9731903 | 0.79 | MAPT (0.50) | APEX1ALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL6173449 | 0.78 | MAPT (0.47) | APEX1ALDH1A1MAPTCA2HPGD | |
| SCHEMBL2001946 | 0.78 | APEX1 (0.43) | APEX1ALDH1A1MAPTHPGDHSP90AA1 | |
| SCHEMBL8427051 | 0.77 | CA2 (0.62) | APEX1ALDH1A1MAPTCA2MEN1 | |
| SCHEMBL2001981 | 0.75 | APEX1 (0.72) | APEX1ALDH1A1MAPTCA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | APEX1 4287/4885ALDH1A1 1422/4885MAPT 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.